Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A L Barry

Showing results (381-390 of 420) with videos related to

Pageof 42
Sort By:
The Journal of Antimicrobial Chemotherapy|February 1, 1994
In-vitro activity of five beta-lactam/beta-lactamase inhibitor combinations against consecutive isolates of the Enterobacteriaceae and Pseudomonas aeruginosaJ C McLaughlin, A L Barry, P C Fuchs, et al.
Antimicrobial Agents and Chemotherapy|December 1, 1986
Antimicrobial activity of Ro 15-8074, active metabolite of a new oral cephalosporin (Ro 15-8075), against 7,775 recent clinical isolatesR N Jones, P C Fuchs, A L Barry, et al.
American Journal of Clinical Pathology|November 1, 1979
In-vitro activities of cefamandole and cephalothin against 1,881 clinical isolates. A multi-center studyA L Barry, F D Schoenknect, S Shadomy, et al.
Antimicrobial Agents and Chemotherapy|January 1, 1979
Interpretive criteria for cefamandole and cephalothin disk diffusion susceptibility testsA L Barry, F D Schoenknecht, S Shadomy, et al.
Diagnostic Microbiology and Infectious Disease|April 1, 1986
In vitro activity of DJ-6783 (a keto carboxylic acid) compared with six other orally administered antimicrobial agentsR N Jones, L W Ayers, A L Barry, et al.
Journal of Clinical Microbiology|November 29, 2001
Standardization of broth microdilution and disk diffusion susceptibility tests for Actinobacillus pleuropneumoniae and Haemophilus somnus: quality control standards for ceftiofur, enrofloxacin, florfenicol, gentamicin, penicillin, tetracycline, tilmicosin, and trimethoprim-sulfamethoxazoleP F McDermott, A L Barry, R N Jones, et al.
Diagnostic Microbiology and Infectious Disease|May 1, 1987
RO 23-6240 (AM-833), a new fluoroquinolone: in vitro antimicrobial activity and tentative disk diffusion interpretive criteriaP C Fuchs, R N Jones, A L Barry, et al.
Diagnostic Microbiology and Infectious Disease|May 1, 1987
Quality control limits for microdilution susceptibility tests with aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime, and cefonicidA L Barry, T L Gavan, R N Jones, et al.
Diagnostic Microbiology and Infectious Disease|July 1, 1986
In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteriaP C Fuchs, R N Jones, A L Barry, et al.
The Journal of Antimicrobial Chemotherapy|October 7, 2009
Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility testsR N Jones, A L Barry, C Thornsberry, et al.
Pageof 42

Showing results (381-390 of 420) with videos related to

Sort By:
Pageof 42
The Journal of Antimicrobial Chemotherapy|February 1, 1994
In-vitro activity of five beta-lactam/beta-lactamase inhibitor combinations against consecutive isolates of the Enterobacteriaceae and Pseudomonas aeruginosaJ C McLaughlin, A L Barry, P C Fuchs, et al.
Antimicrobial Agents and Chemotherapy|December 1, 1986
Antimicrobial activity of Ro 15-8074, active metabolite of a new oral cephalosporin (Ro 15-8075), against 7,775 recent clinical isolatesR N Jones, P C Fuchs, A L Barry, et al.
American Journal of Clinical Pathology|November 1, 1979
In-vitro activities of cefamandole and cephalothin against 1,881 clinical isolates. A multi-center studyA L Barry, F D Schoenknect, S Shadomy, et al.
Antimicrobial Agents and Chemotherapy|January 1, 1979
Interpretive criteria for cefamandole and cephalothin disk diffusion susceptibility testsA L Barry, F D Schoenknecht, S Shadomy, et al.
Diagnostic Microbiology and Infectious Disease|April 1, 1986
In vitro activity of DJ-6783 (a keto carboxylic acid) compared with six other orally administered antimicrobial agentsR N Jones, L W Ayers, A L Barry, et al.
Journal of Clinical Microbiology|November 29, 2001
Standardization of broth microdilution and disk diffusion susceptibility tests for Actinobacillus pleuropneumoniae and Haemophilus somnus: quality control standards for ceftiofur, enrofloxacin, florfenicol, gentamicin, penicillin, tetracycline, tilmicosin, and trimethoprim-sulfamethoxazoleP F McDermott, A L Barry, R N Jones, et al.
Diagnostic Microbiology and Infectious Disease|May 1, 1987
RO 23-6240 (AM-833), a new fluoroquinolone: in vitro antimicrobial activity and tentative disk diffusion interpretive criteriaP C Fuchs, R N Jones, A L Barry, et al.
Diagnostic Microbiology and Infectious Disease|May 1, 1987
Quality control limits for microdilution susceptibility tests with aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime, and cefonicidA L Barry, T L Gavan, R N Jones, et al.
Diagnostic Microbiology and Infectious Disease|July 1, 1986
In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteriaP C Fuchs, R N Jones, A L Barry, et al.
The Journal of Antimicrobial Chemotherapy|October 7, 2009
Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility testsR N Jones, A L Barry, C Thornsberry, et al.
Pageof 42